Claims for Patent: 11,571,428

Summary for Patent: 11,571,428

Title:	Pharmaceutical compositions comprising meloxicam
Abstract:	Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Inventor(s):	Herriot Tabuteau
Assignee:	Axsome Therapeutics Inc
Application Number:	US17/392,456
Patent Claims:	1. A method of treating migraine, comprising orally administering a combination of a meloxicam and a rizatriptan to a human being in need thereof, wherein the meloxicam is orally administered to the human being at a dose of about 18 mg to about 23 mg of meloxicam free acid, or a molar equivalent amount of a salt of meloxicam. 2. The method of claim 1, wherein the rizatriptan is orally administered to the human being at a dose of about 8 mg to about 13 mg of rizatriptan free base, or a molar equivalent amount of a salt of rizatriptan. 3. A method of treating migraine, comprising orally administering a combination of a meloxicam and a rizatriptan to a human being in need thereof, wherein the meloxicam is orally administered to the human being at a dose of about 18 mg to about 23 mg of meloxicam free acid, or a molar equivalent amount of a salt of meloxicam, and wherein the human being experiences a reduction in migraine pain at one hour after the combination is orally administered. 4. The method of claim 2, wherein the human being experiences a reduction in migraine pain at 24 hours after the combination is orally administered. 5. The method of claim 2, wherein the human being is experiencing moderate to severe migraine pain. 6. The method of claim 2, wherein the combination contains about 20 mg of the meloxicam free acid, or the molar equivalent amount of the salt form of meloxicam. 7. The method of claim 2, wherein the human being is experiencing photophobia. 8. The method of claim 7, wherein the human being experiences a reduction in photophobia at two hours after the combination is orally administered. 9. The method of claim 8, wherein the combination contains about 20 mg of the meloxicam free acid, or the molar equivalent amount of the salt form of meloxicam. 10. The method of claim 2, wherein the human being is experiencing phonophobia. 11. The method of claim 10, wherein the human being experiences a reduction in phonophobia at two hours after the combination is orally administered. 12. The method of claim 11, wherein the combination contains about 20 mg of the meloxicam free acid, or the molar equivalent amount of the salt form of meloxicam. 13. The method of claim 2, wherein the human being is experiencing nausea. 14. The method of claim 13, wherein the human being experiences a reduction in nausea at two hours after the combination is orally administered. 15. The method of claim 14, wherein the combination contains about 20 mg of the meloxicam free acid, or the molar equivalent amount of the salt form of meloxicam. 16. The method of claim 2, wherein the migraine is associated with an aura. 17. The method of claim 2, wherein the human being has a reduced use of pain medication other than meloxicam, as compared to the use of the pain medication that would have occurred without receiving the meloxicam. 18. The method of claim 2, wherein the human being has a reduced use of pain medication other than meloxicam, wherein the use of the pain medication is reduced by at least about 20% as compared to the use of the pain medication that would have occurred without receiving the meloxicam. 19. The method of claim 2, wherein the human being has a Tmax of meloxicam that is two hours or less after the combination is orally administered. 20. The method of claim 2, wherein the human being has a Tmax of meloxicam that is one hour or less after the combination is orally administered. 21. The method of claim 3, wherein the human being experiences a reduction in migraine pain at 24 hours after the combination is orally administered. 22. The method of claim 3, wherein the human being is experiencing moderate to severe migraine pain. 23. The method of claim 3, wherein the combination contains about 20 mg of the meloxicam free acid, or the molar equivalent amount of the salt form of meloxicam. 24. The method of claim 3, wherein the human being is experiencing photophobia, and the human being experiences a reduction in photophobia at two hours after the combination is orally administered. 25. The method of claim 3, wherein the human being is experiencing phonophobia, and the human being experiences a reduction in phonophobia at two hours after the combination is orally administered. 26. The method of claim 3, wherein the human being is experiencing nausea, and the human being experiences a reduction in nausea at two hours after the combination is orally administered. 27. The method of claim 3, wherein the migraine is associated with an aura. 28. The method of claim 3, wherein the human being has a reduced use of pain medication other than meloxicam, as compared to the use of the pain medication that would have occurred without receiving the meloxicam. 29. The method of claim 3, wherein the human being has a reduced use of pain medication other than meloxicam, wherein the use of the pain medication is reduced by at least about 20% as compared to the use of the pain medication that would have occurred without receiving the meloxicam. 30. The method of claim 3, wherein the human being has a Tmax of meloxicam that is one hour or less after the combination is orally administered.